<SEC-DOCUMENT>0001309014-16-001509.txt : 20161220
<SEC-HEADER>0001309014-16-001509.hdr.sgml : 20161220
<ACCEPTANCE-DATETIME>20161220083114
ACCESSION NUMBER:		0001309014-16-001509
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20161107
FILED AS OF DATE:		20161220
DATE AS OF CHANGE:		20161220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC & OTHER ELECTRICAL EQUIPMENT (NO COMPUTER EQUIP) [3600]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05146-01
		FILM NUMBER:		162060316

	BUSINESS ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KONINKLIJKE PHILIPS ELECTRONICS NV
		DATE OF NAME CHANGE:	19981217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>htm_10667.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- HTML Header Page -->
<HTML>
<HEAD>
<TITLE>
Koninklijke Philips N.V.&nbsp;-&nbsp;Form&nbsp;6-K
</TITLE>
</HEAD>
<!-- End HTML Header Page --><!-- Cover Page Header -->
<BODY bgcolor=white text=black>
<HR NOSHADE>
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P align="center">
<FONT size="+1"><B>
UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B>
</P>

<P>
<CENTER>
<FONT SIZE="+2" FACE="Arial"><B>FORM 6-K</B></FONT><BR>

</CENTER>
</P>

<P>
<CENTER>
<FONT size="+1">
REPORT OF FOREIGN PRIVATE ISSUER<BR>PURSUANT TO RULE 13a-16 OR 15d-16<BR>UNDER THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</CENTER>
</P>
<P>
<CENTER>
November 7, 2016
</CENTER>
</P>
<P>
<CENTER>

</CENTER>
</P>
<!-- End Cover Page Header -->
<!-- Cover Page Registrant -->
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	<FONT SIZE="+2"><B>Koninklijke Philips N.V.</B></FONT><BR>
	<FONT SIZE="-7">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="CENTER" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	<FONT SIZE="-1">(Translation of registrant&#146;s name into English)</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	&nbsp;
    </TD>
  </TR>
<TR><TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5"><FONT FACE="Courier" SIZE="+0">The Netherlands</FONT><BR><FONT SIZE="-7">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</FONT></TD></TR><TR><TD VALIGN="CENTER" ALIGN="CENTER" WIDTH="100%" COLSPAN="5"><FONT SIZE="-1">(Jurisdiction of incorporation or organization)</FONT></TD></TR><TR><TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">&nbsp;</TD></TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
      <FONT FACE="Courier" SIZE="+0">Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
        <FONT SIZE="-7">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</FONT><BR>
	    <FONT SIZE="-1">(Address of principal executive office)</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	&nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Cover Page Registrant -->
<!-- Checkboxes Page -->
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%" COLSPAN="5">
	Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:&nbsp;&nbsp;[<FONT FACE="Courier">x</FONT>]&nbsp;Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]&nbsp;Form 40-F
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;[<FONT FACE="Courier">x</FONT>]&nbsp;No
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>
</TABLE>

<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
        If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):&nbsp;&nbsp;&nbsp;<FONT FACE="Courier"><U>&nbsp;n/a&nbsp;</U></FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Checkboxes Page -->
<!-- HR Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End HR Page Break --><!-- Report Page -->
<FONT SIZE="3">
<PRE>
Philips and Masimo sign multi-year business partnership agreement in patient
monitoring and select therapy solutions
</PRE>
</FONT>
<!-- End Report Page -->
<!-- Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
 <!-- Page Break  -->
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End Page Break -->
<!-- Signatures Page Header -->
<FONT SIZE="+1">
<CENTER>
<B>SIGNATURES</B>
</CENTER>
</FONT>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
       &nbsp;
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
       &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Signatures Page Header -->
<!-- Signatures Page Details -->
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       Koninklijke Philips N.V.
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="40%">
       Date: 12/20/2016
    </TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="4%%">
       By:
    </TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="56%">
       /s/ M.J. van Ginneken<BR><HR WIDTH="30%" NOSHADE>
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       Name:&nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
        M.J. van Ginneken
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       Title:
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       General Secretary
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Signatures Page Details -->
<!-- HR Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End HR Page Break --><!-- Exhibit Index Header Page -->
<CENTER>
<FONT SIZE="+1"><B>
EXHIBIT&nbsp;INDEX
</B></FONT>
</CENTER>
<BR>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
  <TR VALIGN="BOTTOM">
    <TD NOWRAP ALIGN="LEFT" WIDTH="8%">
      <FONT SIZE="-1"><B>Exhibit No.</B></FONT>
    </TD>
    <TD WIDTH="15%">
      &nbsp;
    </TD>
    <TD NOWRAP ALIGN="LEFT" WIDTH="77%">
      <FONT SIZE="-1"><B>Description</B></FONT>
    </TD>
  </TR>
  <TR VALIGN="BOTTOM">
    <TD NOWRAP ALIGN="CENTER" WIDTH="8%">
      <HR SIZE="1" NOSHADE>
    </TD>
    <TD WIDTH="15%">
      &nbsp;
    </TD>
    <TD NOWRAP ALIGN="CENTER" WIDTH="77%">
      <HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
    </TD>
  </TR>
<!-- Exhibit Index Header Page -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- ExhibitIndexFooter -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      &nbsp;
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End ExhibitIndexFooter -->
<!-- HR Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End HR Page Break --><!-- HTML Footer Page -->
</BODY>
</HTML>
<!-- End HTML Footer Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 22pt">Press Information
</FONT>

<P align="left" style="font-size: 22pt"><FONT style="font-size: 11pt">November&nbsp;7, 2016
</FONT>

<P align="left" style="font-size: 11pt"><FONT style="font-size: 12pt"><B>Philips and Masimo sign multi-year business partnership agreement in patient monitoring and
select therapy solutions</B>
</FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><FONT style="font-size: 11pt">&#149;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT style="font-size: 11pt"><I>Multi-year business partnership combines Masimo&#146;s expertise in non-invasive sensor and
signal processing technologies and Philips&#146; expertise in integrated patient monitoring and
therapy solutions</I></FONT></TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Business partnership involves technology integration and marketing and sales cooperation in
North America and certain markets in Asia and Europe</I></TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 11pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Agreement ends all pending lawsuits between the two companies and, in addition to marketing
and integration commitments, includes a cash payment of USD 300&nbsp;million by Philips to Masimo</I></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 11pt"><B>Amsterdam, the Netherlands and Irvine, California &#151; </B>Royal Philips (NYSE: PHG; AEX: PHIA) and Masimo
Corporation (NASDAQ: MASI) today announced a wide-ranging, multi-year business partnership
involving both companies&#146; innovations in patient monitoring and therapy solutions. The partnership
includes joint marketing and sales programs in North America and certain markets in Asia and Europe
for Masimo&#146;s non-invasive sensor technologies, such as its rainbow<sup>&#174;</sup> and SET<sup>&#174;</sup>
platforms, in conjunction with Philips&#146; patient monitoring and select therapy solutions. In
addition, Philips will in the future integrate Masimo SedLine<sup>&#174;</sup> brain function
monitoring, O3&#153; regional oximetry, and Nomoline&#153; capnography technologies in certain Philips
IntelliVue<sup>&#174;</sup> monitors.


<P align="left" style="font-size: 11pt">Philips is a global leader in patient monitoring solutions with a comprehensive product portfolio
ranging from multi-parameter bedside monitors to wearable patient monitors combined with mobile
applications and clinical decision support tools. With a primary focus on prediction and prevention
of patient deterioration, these integrated solutions aim to support clinical workflow and caregiver
efficiencies, and enhance patient care. In 2015, an estimated 275&nbsp;million patients were monitored
using Philips&#146; patient monitoring solutions.


<P align="left" style="font-size: 11pt">Sensor and signal processing technologies are an essential component of patient monitoring
solutions, and Masimo is a prolific innovator in this field. Examples of Masimo&#146;s non-invasive
sensor and signal processing technology innovations include Masimo SET<sup>&#174; </sup>pulse oximetry,
Masimo rainbow<sup>&#174;</sup>&nbsp;Pulse CO-Oximetry and Masimo total hemoglobin (SpHb<sup>&#174;</sup>)
monitoring technology.


<P align="left" style="font-size: 11pt">&#147;This business partnership agreement marks an important day for us and our customers as two leaders
in patient monitoring collaborate to develop solutions designed to enhance clinical outcomes and
patient safety,&#148; said Frans van Houten, CEO of Royal Philips. &#147;I am very satisfied that we have
reached an agreement that is beneficial for both companies and that we have ended our legal
disputes. Going forward, Philips and Masimo will completely focus on jointly delivering meaningful
innovations to our customers, such as the integration of Masimo rainbow<sup>&#174;</sup> technology
across our IntelliVue<sup>&#174;</sup> patient monitoring product range.&#148;


<P align="left" style="font-size: 11pt">&#147;It&#146;s wonderful to think that Masimo and Philips will be working together for the benefit of
patients and clinicians around the world,&#148; said Joe Kiani, Chairman and CEO of&nbsp;Masimo. &#147;I am
delighted that we were able to reach this important agreement which allows us to focus on the
future to deliver the solutions that our customers have been looking for.&#148;


<P align="left" style="font-size: 11pt">In conjunction with the appropriate Philips patient monitoring platform, Masimo&#146;s rainbow SET&#153;
technology analyzes multiple wavelengths of light to accurately measure total hemoglobin (SpHb),
oxygen content (SpOC<sup>&#153;</sup>), carboxyhemoglobin (SpCO<sup>&#174;</sup>), methemoglobin
(SpMet<sup>&#174;</sup>) and Pleth Variability Index (PVI<sup>&#174;</sup>) non-invasively and continuously.
Continuous monitoring of SpHb on a Philips monitor at the point of care provides clinicians with
real-time visibility to changes in hemoglobin in between invasive blood samplings.


<P align="left" style="font-size: 11pt"><B>Anticipated cash flow and income consequences for Philips</B>
<BR>
As part of the business partnership agreement, Philips and Masimo have agreed to end all pending
lawsuits between the two companies, which includes that Philips is released from paying the USD 467
million (approximately EUR 428&nbsp;million) jury verdict that was awarded to Masimo in October, 2014.
Philips has agreed to make a USD 300&nbsp;million cash payment (approximately EUR 275&nbsp;million) to Masimo
in the fourth quarter of 2016; and to invest in the relationship by making certain marketing and
product integration commitments over the coming years. Entering into the business partnership
agreement has minimal impact on income from operations (EBIT)&nbsp;in the fourth quarter of 2016.


<P align="left" style="font-size: 11pt"><B>Anticipated cash flow and income consequences for Masimo</B>
<BR>
As the result of anticipated legal fee savings during the fourth fiscal quarter, Masimo now expects
its fiscal 2016 GAAP earnings per diluted share, exclusive of the impact of the business
partnership agreement, to be $2.14, up from $2.13. Masimo expects to use some of the after-tax
proceeds from the business partnership agreement to repay amounts outstanding under its revolving
line of credit. The guidance set forth above is an estimate only and actual performance could
differ.


<P align="left" style="font-size: 11pt"><B>For further information, please contact:</B>


<P align="left" style="font-size: 11pt">Steve Klink
<BR>
Philips Group Communications
<BR>
Tel.: &#043;31 6 10888824
<BR>
E-mail: <U>steve.klink@philips.com</U>


<P align="left" style="font-size: 11pt">Vanessa Bruinsma-Kleijkers
<BR>
Philips Investor Relations
<BR>
Tel.: &#043;31 20 5977447
<BR>
Email: <U>Vanessa.Bruinsma-Kleijkers@philips.com</U>


<P align="left" style="font-size: 11pt">Eli Kammerman
<BR>
Masimo Investor Relations
<BR>
Tel.: &#043;1 949-297-7077
<BR>
Email: ekammerman@masimo.com


<P align="left" style="font-size: 11pt">Evan Lamb
<BR>
Masimo Media Contact
<BR>
Tel.: &#043;1 949-396-3376
<BR>
Email: elamb@masimo.com


<P align="left" style="font-size: 11pt"><B>About Royal Philips</B>
<BR>
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving
people&#146;s health and enabling better outcomes across the health continuum from healthy living and
prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep
clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands,
the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health
informatics, as well as in consumer health and home care. Philips&#146; health technology portfolio
generated 2015 sales of EUR 16.8&nbsp;billion and employs approximately 70,000 employees with sales and
services in more than 100 countries. News about Philips can be found at
<U>www.philips.com/newscenter</U>.


<P align="left" style="font-size: 11pt"><B>About Masimo</B>
<BR>
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our
mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring
to new sites and applications. In 1995, the company debuted Masimo SET<sup>&#174;</sup>&nbsp;Measure-through
Motion and Low Perfusion<sup>&#153;</sup>&nbsp;pulse oximetry, which has been shown in multiple studies to
significantly reduce false alarms and accurately monitor for true alarms. Masimo SET<sup>&#174;</sup>&nbsp;is
estimated to be used on more than 100&nbsp;million patients in leading hospitals and other healthcare
settings around the world. In 2005, Masimo introduced rainbow<sup>&#174; </sup>Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood constituents that previously
could only be measured invasively, including total hemoglobin (SpHb<sup>&#174;</sup>), oxygen content
(SpOC<sup>&#153;</sup>), carboxyhemoglobin (SpCO<sup>&#174;</sup>), methemoglobin (SpMet<sup>&#174;</sup>), and
more recently, Pleth Variability Index (PVI<sup>&#174;</sup>) and Oxygen Reserve Index
(ORi<sup>&#153;</sup>), in addition to SpO<sub>2</sub>, pulse rate, and perfusion index (PI). In 2014,
Masimo introduced Root<sup>&#174;</sup>, an intuitive patient monitoring and connectivity platform with
the Masimo Open Connect<sup>&#153;</sup>&nbsp;(MOC-9<sup>&#153;</sup>) interface. Masimo is also taking an active
leadership role in mHealth with products such as the Radius-7<sup>&#174;</sup>&nbsp;wearable patient monitor
and the MightySat<sup>&#153;</sup>&nbsp;fingertip pulse oximeter. Additional information about Masimo and its
products may be found at&nbsp;<U>www.masimo.com</U>. All published clinical studies on Masimo products
can be found at&nbsp;<U>www.masimo.com/cpub/clinical-evidence.htm</U>.


<P align="left" style="font-size: 11pt"><B>Forward-Looking Statements &#150; Royal Philips</B>
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements.


<P align="left" style="font-size: 11pt"><B>Forward-Looking Statements &#150; Masimo</B>
<BR>
This press release includes forward-looking statements as defined in Section&nbsp;27A of the Securities
Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and uncertainties, all of
which are difficult to predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our forward-looking statements
as a result of various risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks related to our belief that
Masimo&#146;s unique noninvasive measurement technologies contribute to positive clinical outcomes and
patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other factors discussed in the &#147;Risk
Factors&#148; section of our most recent reports filed with the Securities and Exchange Commission
(&#147;SEC&#148;), which may be obtained for free at the SEC&#146;s website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which speak only as of
today&#146;s date. We do not undertake any obligation to update, amend or clarify these statements or
the &#147;Risk Factors&#148; contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the applicable
securities laws.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
